Innovation, quality, international development, competitiveness.


These are the leading principles of Fidia Pharma Group.


Principles we are committed to deliver, with our people, ideas and passion, approaching the market with a firm grip on reality and developing value-added solutions to healthcare challenges, which is the demand placed on us.

Drawing on the strengths of the parent company, Fidia Pharma Middle East F.Z.E. is focused on providing healthcare professionals and consumers with innovative products, for the treatment of commonly occurring pathologies with serious social and economic impact.


Find out more
26/07/2021

Fidia announces the FDA Orphan Drug designation for ONCOFID for the treatment of malignant mesothelioma, the cancer caused by exposure to asbestos

Abano Terme (PD), July 26th, 2021 - Fidia Farmaceutici, an Italian company world leader in the…
Find out more
23/03/2021

Fidia a signé un accord avec Sanofi pour l'acquisition d'un portefeuille de médicaments anti-inflammatoires

Grâce à cette récente opération, la société a renforcé sa présence sur le marché des médicaments sur…
Find out more
23/03/2021

Fidia signed a binding agreement with Sanofi for the acquisition of a Sanofi portfolio of anti-inflammatory drugs

Based on this recent operation, the company has strengthened its presence in the prescription drug…
Find out more

Fidia
Farmaceutici S.p.A.
Website

Find out our Corporate Website:

Go to the website

Fidia’s other websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Middle East product portfolio focalizes primarily on therapeutic areas such as joint healthcare and tissue repair.

Fidia Pharma Middle East is focused on providing consumers with innovative products that offer quality, safety and performance and exploring innovative channel strategies to access customers and consumers, such as healthcare e-commerce.